EZH2 and acute myeloid leukemia: Mechanistically, it has been suggested, via ex vivo and in vivo experiments in AML cells and patient samples, that EZH2 inhibition (GSK126) may participate in the chromatin decondensing of AML blasts via decreased H3K27me3, and subsequently this may increase chemosensitivity when used in conjunction with standard chemotherapy [142].